Research progress on neoadjuvant chemoradiotherapy combined with immunotherapy in locally advanced rectal cancer
10.3760/cma.j.cn113030-20210812-00300
- VernacularTitle:局部晚期直肠癌新辅助放化疗联合免疫治疗的研究进展
- Author:
Yaqi WANG
1
;
Fan XIA
;
Zhen ZHANG
Author Information
1. 复旦大学附属肿瘤医院放射治疗中心，复旦大学上海医学院肿瘤学系，上海市放射肿瘤学重点实验室，上海市放射治疗临床医学研究中心，上海 200032
- Keywords:
Rectal neoplasms, locally advanced;
Neoadjuvant chemoradiotherapy;
Immunotherapy;
Research progress
- From:
Chinese Journal of Radiation Oncology
2023;32(1):70-74
- CountryChina
- Language:Chinese
-
Abstract:
For locally advanced (T 3-4/N +M 0) rectal cancer (LARC), neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) is the standard treatment, which have been demonstrated to decrease the local recurrence rate and increase the tumor response grade. However, the distant metastasis remains an unresolved issue. Radiotherapy and immunotherapy can supplement each other and the combination of the two treatments has a good theoretical basis. Recently, multiple clinical trials are ongoing in terms of the combination of nCRT and immunotherapy in LARC. These trials have achieved promising short-term efficacy in both microsatellite instability-high (MSI-H) and microsatellite stable (MSS) rectal cancers, which could further improve the rate of tumor response and rate of pathological complete response, increase the possibility of organ preservation and "watch and wait" approach. Large-scale clinical trials need to be performed in the future to demonstrate these findings and to improve long-term prognosis.
